We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+8.21%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$337M
AUM Growth
+$3.84M
Cap. Flow
-$22.8M
Cap. Flow %
-6.78%
Top 10 Hldgs %
34.36%
Holding
109
New
18
Increased
35
Reduced
37
Closed
13

Top Buys

Rank Stock Value
1
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$9.48M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.12M
3
CAH icon
Cardinal Health
CAH
+$6.74M
4
AGN
Allergan plc
AGN
+$5.18M
5
CLVS
Clovis Oncology, Inc.
CLVS
+$4.64M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$11.3M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.87M
3
GILD icon
Gilead Sciences
GILD
+$5.35M
4
CFNL
Cardinal Financial Corp
CFNL
+$5.03M
5
FRX
FOREST LABORATORIES INC
FRX
+$4.44M

Sector Composition

Rank Sector Weight
1 Healthcare 85%
2 Financials 1.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIIB icon
1
Biogen
BIIB
$30B
$15.8M 4.68%
50,000
+8,952
+22% +$2.69M
COV
2
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
$15.4M 4.58%
171,000
+126,779
+287% +$9.48M
GILD icon
3
Gilead Sciences
GILD
$162B
$14.9M 4.43%
180,000
-68,735
-28% -$5.35M
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
$14.5M 4.31%
93,000
-18,731
-17% -$2.96M
CELG
5
DELISTED
Celgene Corp
CELG
$13.5M 4%
156,781
+39,999
+34% +$3.04M
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$121B
$9.62M 2.85%
+101,600
New +$7.12M
BMRN icon
7
BioMarin Pharmaceuticals
BMRN
$11.6B
$9.33M 2.77%
150,000
+4,736
+3% +$286K
ALKS icon
8
Alkermes
ALKS
$8.22B
$8.46M 2.51%
168,000
-33,277
-17% -$1.53M
INCY icon
9
Incyte
INCY
$24.2B
$7.51M 2.23%
133,000
+25,962
+24% +$1.33M
CAH icon
10
Cardinal Health
CAH
$53.9B
$6.79M 2.01%
+99,000
New +$6.74M
AGN
11
DELISTED
Allergan Inc
AGN
$6.77M 2.01%
40,000
+12,484
+45% +$1.94M
REGN icon
12
Regeneron Pharmaceuticals
REGN
$78.5B
$6.36M 1.89%
22,500
-33,292
-60% -$9.87M
AGN
13
DELISTED
Allergan plc
AGN
$5.58M 1.65%
+25,000
New +$5.18M
SLXP
14
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$5.37M 1.59%
43,493
-10,295
-19% -$1.14M
BSX icon
15
Boston Scientific
BSX
$69.5B
$5.3M 1.57%
415,000
+130,022
+46% +$1.69M
ACAD icon
16
Acadia Pharmaceuticals
ACAD
$4.43B
$5.2M 1.54%
230,000
+53,117
+30% +$1.11M
CI icon
17
Cigna
CI
$73.7B
$5.06M 1.5%
55,000
+5,865
+12% +$503K
PCYC
18
DELISTED
PHARMACYCLICS INC
PCYC
$4.93M 1.46%
55,000
-42,286
-43% -$3.97M
CYH icon
19
Community Health Systems
CYH
$393M
$4.63M 1.37%
123,420
+40,187
+48% +$1.34M
CYBX
20
DELISTED
CYBERONICS INC
CYBX
$4.62M 1.37%
74,000
+10,246
+16% +$624K
MRK icon
21
Merck
MRK
$322B
$4.51M 1.34%
81,744
+1,415
+2% +$77.2K
BMY icon
22
Bristol-Myers Squibb
BMY
$133B
$4.12M 1.22%
85,000
-1,815
-2% -$89.4K
MDVN
23
DELISTED
MEDIVATION, INC.
MDVN
$4.01M 1.19%
104,000
-105,010
-50% -$3.54M
MCK icon
24
McKesson
MCK
$100B
$4M 1.19%
21,500
-5,120
-19% -$911K
PODD icon
25
Insulet
PODD
$11.5B
$3.97M 1.18%
100,000
+41,039
+70% +$1.58M
1
2 3 4 5

Similar funds

BBI
Baxter Bros Inc Riverside, Connecticut $810M AUM 16.24% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
DWA
Dorsey Wright & Associates Pasadena, California $807M AUM 65.46% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2014 Portfolio in Review

As of Q2 2014, Rhenman & Partners Asset Management held 109 positions worth $337M, up 1.2% from $333M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $22.8M in Q2 2014, closing 13 positions and reducing 37 holdings. Its most notable exit was Pfizer, an estimated $11.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 80% a quarter earlier, followed by Financials.

Against the trend, Rhenman & Partners Asset Management opened a new position in Vertex Pharmaceuticals worth $9.62M.

  • Rhenman & Partners Asset Management's largest Q2 2014 buy was Vertex Pharmaceuticals: 101,600 shares worth $9.62M.
  • Rhenman & Partners Asset Management added most to COVIDIEN PLC COM SHS NEW (IRELAND) in Q2 2014, an estimated $9.48M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2014 reduction was Regeneron Pharmaceuticals, cutting an estimated $9.87M.
  • Rhenman & Partners Asset Management fully exited Pfizer in Q2 2014, selling an estimated $11.3M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 34% of its $337M portfolio in Q2 2014.
  • Rhenman & Partners Asset Management opened 18 new positions and closed 13 in Q2 2014.
  • Rhenman & Partners Asset Management's portfolio value rose 1.2% quarter-over-quarter to $337M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2014, filed 31 Jul 2014.